Sana Ali

Sana Ali

Auto-generated profile, based on publicly available information

Sana Ali

Department of Medicine, Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
ZZZeynep B. Zengin
Zeynep B. Zengin
ACAlexander Chehrazi-Raffle
Alexander Chehrazi-Raffle
NSNicholas Salgia
Nicholas Salgia
RMRamya Muddasani
Ramya Muddasani
SASana Ali
Sana Ali
SPSumanta K Pal
Sumanta K Pal

26 March 2025 in Exploration of Targeted Anti-tumor Therapy
Verified
Journal Article
Open access
PDF file
EBEljie Isaak Bragasin
Eljie Isaak Bragasin
JCJustin Cheng
Justin Cheng
LFLauren Ford
Lauren Ford
DPDarin Poei
Darin Poei
SASana Ali
Sana Ali
RHRobert Hsu
Robert Hsu
Small cell lung cancer (SCLC) is an aggressive tumor characterized by early metastasis and resistance to treatment, making it a prime target for therapeutic investigation. The current standard of care for frontline treatment involves a combination of chemotherapeutic agents and immune checkpoint inhibitors (ICIs), though durability of response remains limited. The genetic heterogeneity of SCLC also complicates the development of new therapeutic options. Adoptive cell therapies show promise by targeting specific mutations in order to increase efficacy and minimize toxicity. There has been significant investigation in three therapeutic classes for application towards SCLC: antibody drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), and chimeric antigen receptor (CAR)-T cell therapies. This review summarizes the recent advances and challenges in the development of adoptive cell therapies. Genetic targets such as delta-like ligand 3 (DLL3), trophoblast cell surface antigen 2 (Trop2), B7-H3 (CD276), gangliosides disialoganglioside GD2 (GD2) and ganglioside GM2 (GM2) have been found to be expressed in SCLC, which makes them prime targets for therapy development. While investigated therapies such as rovalpituzumab tesirine (Rova-T) have failed, several insights from these trials have led to the development of compelling new agents such as sacituzumab govitecan (SG), ifinatamab deruxtecan (I-DXd), tarlatamab, and DLL3-targeted CAR-T cells. Advancing development of molecular testing and improving targeted approaches remain integral to pushing forward the progress of adoptive cell therapies in SCLC.

1 February 2025 in Cancer Research Communications
Verified
Journal Article
Open access
DPDarin Poei
Darin Poei
SASana Ali
Sana Ali
JTJacob S. Thomas
Jacob S. Thomas
JNJorge Nieva
Jorge Nieva
RHRobert Hsu
Robert Hsu
Race and ethnicity affect the distribution of molecular alterations seen in patients with non–small cell lung cancer (NSCLC). Although anaplastic lymphoma kinase (ALK) alterations are known to occur in 4% to 5% of the population, data specific to the Hispanic population remain limited. This study describes the real-world incidence of ALK alterations in Hispanic patients with NSCLC treated at a large academic institution in Los Angeles, California, United States, to further elucidate the underlying factors that shape differences in mutational profiles. A total of 607 patients with NSCLC treated at Los Angeles General Medical Center (n = 172) and the University of Southern California Norris Comprehensive Cancer Center (n = 435) who received comprehensive genomic profiling were evaluated from January 2015 to June 2023. The Fisher exact test and multivariate logistic regression were incorporated for statistical analysis. Hispanic patients exhibited a higher incidence of ALK alterations (12.76%, n = 18/141) than non-Hispanic patients (5.36%, n = 23/466; P = 0.0046). Multivariate logistic regression showed that Hispanic ethnicity (HR, 2.393; 95% confidence interval, 1.115–5.092) and age at diagnosis (HR, 0.9325; 95% confidence interval, 0.9081–0.9558) were significant variables in ALK alteration incidence, and 55.81% (n = 24) of ALK alterations were initially found via comprehensive genomic profiling. This study highlights a significantly higher incidence of ALK alterations among Hispanic patients with NSCLC, emphasizing the impact of race and ethnicity on molecular alterations. Future research is required to evaluate this trend in a larger, more diverse cohort and investigate the roles of environmental factors and tumor microenvironments in influencing ALK alteration prevalence. Significance: This study identified a higher incidence of ALK alterations in Hispanic patients with NSCLC (12.76%) compared with that in non-Hispanic patients (5.36%) treated at a large academic center in Los Angeles, highlighting the impact of race on molecular alteration profiles and emphasizing the need to increase access to molecular analyses for this population. The variability in mutational alterations may be influenced by biological and environmental factors.

1 April 2023 in JCO Oncology Practice
Verified
Journal Article
Closed access
RERaisa Epistola
Raisa Epistola
BHBrian Ho
Brian Ho
SLSally Leong
Sally Leong
SASana Ali
Sana Ali
RGRachel Germono
Rachel Germono
JYJames J. Yeh
James J. Yeh
PURPOSE: Timely radiographic studies are essential to oncology care. At our institution, a safety net hospital in a large metropolitan area, baseline assessment determined that the overwhelming majority of outpatient computed tomographic (CT) scans for oncology patients were overdue and not scheduled within 2 weeks of their first requested date. METHODS: We conducted a series of structured, interdisciplinary meetings including staff from radiology, oncology, scheduling, and administration to critically review the scheduling process utilizing Lean Kaizen quality improvement methods. A new workflow was developed in which clinic staff scheduled CT scans before clinic discharge. Three months after our initial meeting, the new workflow was launched. We set a target of decreasing the percentage of overdue scans to below 20%. RESULTS: At baseline, 87% (65 of 75) of CT scans awaiting scheduling were overdue. Data were gathered at 5 and 10 weeks after implementation of our workflow. The percentage of CT scans overdue for scheduling was 17% (9 of 53) at 5 weeks and 0.97% (1 of 103) at 10 weeks after implementation. Clinic visit durations were not affected. CONCLUSION: The Lean Kaizen QI model was successful in decreasing the rate of oncology patients overdue for CT scan scheduling with minimal effects on clinic visit durations. This study demonstrated the importance of interdepartmental collaboration and continuous monitoring for improvement. Given the success of this project, this workflow will be expanded to other outpatient clinics within our institution.

10 February 2025
Verified
Other
Open access
DPDarin Poei
Darin Poei
SASana Ali
Sana Ali
JTJacob S. Thomas
Jacob S. Thomas
JNJorge Nieva
Jorge Nieva
RHRobert Hsu
Robert Hsu
Logistic regression for ALK alterations evaluating Hispanic ethnicity and controlling for site of treatment, age at initial diagnosis, gender, and smoking